Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Joseph

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Biological Chemistry|September 10, 2010
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophyChristopher R Orr, Heather L Montie, Yuhong Liu, et al.
Cancer Discovery|June 20, 2013
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509James D Joseph, Nhin Lu, Jing Qian, et al.
Molecular Endocrinology (Baltimore, Md.)|May 23, 2009
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitroDaniel E Frigo, Andrea B Sherk, Bryan M Wittmann, et al.
Journal of Medicinal Chemistry|August 9, 2018
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast CancerJohnny Nagasawa, Steven Govek, Mehmet Kahraman, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2015
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Johnny Y Nagasawa, Karensa L Douglas, et al.
Journal of Medicinal Chemistry|April 17, 2015
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer XenograftsAndiliy Lai, Mehmet Kahraman, Steven Govek, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2018
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Celine Bonnefous, Jackaline D Julien, et al.
Cancer Research|January 24, 2012
ARN-509: a novel antiandrogen for prostate cancer treatmentNicola J Clegg, John Wongvipat, James D Joseph, et al.
Elife|July 14, 2016
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancerJames D Joseph, Beatrice Darimont, Wei Zhou, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|September 10, 2010
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophyChristopher R Orr, Heather L Montie, Yuhong Liu, et al.
Cancer Discovery|June 20, 2013
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509James D Joseph, Nhin Lu, Jing Qian, et al.
Molecular Endocrinology (Baltimore, Md.)|May 23, 2009
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitroDaniel E Frigo, Andrea B Sherk, Bryan M Wittmann, et al.
Journal of Medicinal Chemistry|August 9, 2018
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast CancerJohnny Nagasawa, Steven Govek, Mehmet Kahraman, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2015
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Johnny Y Nagasawa, Karensa L Douglas, et al.
Journal of Medicinal Chemistry|April 17, 2015
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer XenograftsAndiliy Lai, Mehmet Kahraman, Steven Govek, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2018
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Celine Bonnefous, Jackaline D Julien, et al.
Cancer Research|January 24, 2012
ARN-509: a novel antiandrogen for prostate cancer treatmentNicola J Clegg, John Wongvipat, James D Joseph, et al.
Elife|July 14, 2016
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancerJames D Joseph, Beatrice Darimont, Wei Zhou, et al.
Pageof 3